气候变化领域集成服务门户(CCPortal): Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

CCPortal

DOI	10.1073/pnas.2026207118
	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
	Tscherne A.; Hendrik Schwarz J.; Rohde C.; Kupke A.; Kalodimou G.; Limpinsel L.; Okba N.M.A.; Bošnjak B.; Sandrock I.; Odak I.; Halwe S.; Sauerhering L.; Brosinski K.; Liangliang N.; Duell E.; Jany S.; Freudenstein A.; Schmidt J.; Werner A.; Serra M.G.; Klüver M.; Guggemos W.; Seilmaier M.; Wendtner C.-M.; Förster R.; Haagmans B.L.; Becker S.; Sutter G.; Volz A.
发表日期	2021
ISSN	0027-8424
卷号	118 期号:28
英文摘要	Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based on modified vaccinia virus Ankara (MVA) against the Middle East respiratory syndrome coronavirus (MERS-CoV), which causes an infection in humans similar to SARS and COVID-19. Here,we describe the construction and preclinical characterization of a recombinant MVA expressing full-length SARS-CoV-2 spike (S) protein (MVA-SARS-2-S). Genetic stability and growth characteristics of MVA-SARS-2-S, plus its robust expression of S protein as antigen, make it a suitable candidate vaccine for industrial-scale production. Vaccinated mice produced S-specific CD8+ T cells and serum antibodies binding to S protein that neutralized SARS-CoV-2. Primeboost vaccination with MVA-SARS-2-S protected mice sensitized with a human ACE2-expressing adenovirus from SARS-CoV-2 infection. MVA-SARS-2-S is currently being investigated in a phase I clinical trial as aspirant for developing a safe and efficacious vaccine against COVID-19. © 2021 National Academy of Sciences. All rights reserved.
英文关键词	Nonclinical testing; Poxvirus; Vaccine vector; Vaccinia virus
语种	英语
scopus关键词	coronavirus spike glycoprotein; neutralizing antibody; virus antibody; animal; Bagg albino mouse; dose response; genetics; human; immunology; mouse; prevention and control; T lymphocyte; vaccination; Vaccinia virus; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Immunologic; Humans; Mice; Mice, Inbred BALB C; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Vaccination; Vaccinia virus
来源期刊	Proceedings of the National Academy of Sciences of the United States of America
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/238873
作者单位	Division of Virology, Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, 80539, Germany; Division of Virology, Department of Veterinary Sciences, German Center for Infection Research, Munich, 80539, Germany; Institute of Virology, Philipps University Marburg, Marburg, 35037, Germany; Institute of Virology, Marburg, Germany; Center for Infection Research, Giessen-Marburg-Langen, 35392, Germany; Department of Viroscience, Erasmus Medical Center, Rotterdam, 3015 CN, Netherlands; Institute of Immunology, Hannover Medical School, Hannover, 30625, Germany; Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-Universität München, Munich, 80804, Germany; Institute of Immunology, German Center for Infection Research, Hannover, 30625, Germany; Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, 30625, Germany; Institute of Virology, University of Veterinary Medicine Hannover, Hannover, 30559, Germany
推荐引用方式 GB/T 7714	Tscherne A.,Hendrik Schwarz J.,Rohde C.,et al. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination[J],2021,118(28).
APA	Tscherne A..,Hendrik Schwarz J..,Rohde C..,Kupke A..,Kalodimou G..,...&Volz A..(2021).Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.Proceedings of the National Academy of Sciences of the United States of America,118(28).
MLA	Tscherne A.,et al."Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination".Proceedings of the National Academy of Sciences of the United States of America 118.28(2021).